[11C]JMJ-129-d2 for Healthy Volunteers

This trial tests a new tracer, [11C]JMJ-129-d2, which helps doctors visualize a brain protein called PDE4D. This protein is linked to mood, memory, and cognitive issues such as depression and Alzheimer's disease. Researchers aim to find better ways to measure this protein in healthy volunteers using imaging scans. Eligible participants should be in good health and have been screened under specific past protocols. They will undergo imaging scans of the brain and body to assess the tracer's effectiveness. As a Phase 1 trial, this research focuses on understanding how the tracer works in people, offering participants the opportunity to be among the first to receive this new treatment.

You may need to stop taking certain medications for this trial. Specifically, you cannot use PDE4 inhibitors or certain other drugs like CYP3A4 inhibitors and inducers within 7 days before the PET imaging.

Research has shown that [11C]JMJ-129-d2 was safe in early tests. Similar studies and animal research found no major safety issues, suggesting that [11C]JMJ-129-d2 could be safe for humans. The treatment involves a small amount of radiation, commonly used in imaging studies to help doctors visualize certain proteins in the brain. These radiation levels are typical for such studies and are considered safe. Overall, early findings suggest that this treatment is well-tolerated and safe for healthy individuals.¹²³⁴⁵

Researchers are excited about [11C]JMJ-129-d2 because it offers a new way to visualize and understand brain function by targeting specific receptors not previously focused on by standard imaging agents. Unlike traditional imaging agents that may not provide detailed insights into certain neural processes, [11C]JMJ-129-d2 acts on particular molecular targets, potentially offering clearer, more precise brain imaging. This advancement could significantly enhance our understanding of brain activity, paving the way for better diagnostic and therapeutic strategies in the future.

Research has shown that PDE4D is a protein involved in brain functions such as mood, memory, and thinking. Problems with PDE4D may link to depression and Alzheimer's disease. In this trial, all participants will receive [11C]JMJ-129-d2, a new tool designed to visualize PDE4D in the brain through imaging scans. This tool is expected to enhance the detection of PDE4D, potentially aiding in the diagnosis and management of these conditions. Although specific data on the effectiveness of [11C]JMJ-129-d2 is not yet available, it is believed to provide valuable insights into brain health.⁶⁷⁸⁹¹⁰